Headquartered in Tokyo – with a European Research facility in Munich – the company focuses on developing and delivering innovative new medicines, alongside advanced drug discovery and delivery methodologies, which serve patients globally. CPP members benefit from direct connection with EMBL’s world-leading molecular biology research, services, and technology development, and their support enables EMBL to provide additional training opportunities for the next generation of molecular biologists...